300529 健帆生物
交易中 06-08 14:53:33
资讯
新帖
简况
健帆生物（300529）披露健帆转债恢复转股的提示性公告，6月1日股价上涨3.22%
证券之星 · 06-01
健帆生物（300529）披露健帆转债恢复转股的提示性公告，6月1日股价上涨3.22%
健帆生物（300529）披露2025年度权益分派实施公告，5月25日股价下跌1.17%
证券之星 · 05-25
健帆生物（300529）披露2025年度权益分派实施公告，5月25日股价下跌1.17%
健帆生物（300529）披露健帆转债暂停转股公告，5月22日股价上涨0.54%
证券之星 · 05-22
健帆生物（300529）披露健帆转债暂停转股公告，5月22日股价上涨0.54%
健帆生物（300529）披露2025年度股东会决议公告，5月20日股价下跌1.41%
证券之星 · 05-20
健帆生物（300529）披露2025年度股东会决议公告，5月20日股价下跌1.41%
健帆生物最新公告：新产品一次性使用连续性血液净化管路取得医疗器械注册证
证券之星 · 05-11
健帆生物最新公告：新产品一次性使用连续性血液净化管路取得医疗器械注册证
股市必读：健帆生物（300529）4月30日董秘有最新回复
证券之星 · 05-06
股市必读：健帆生物（300529）4月30日董秘有最新回复
每周股票复盘：健帆生物（300529）Q1净利增16.81%
证券之星 · 05-03
每周股票复盘：健帆生物（300529）Q1净利增16.81%
健帆生物：HAHD罗马共识已正式发布
证券之星 · 04-30
健帆生物：HAHD罗马共识已正式发布
健帆生物：细胞因子胆红素吸附树脂项目入选工信部揭榜挂帅
证券之星 · 04-30
健帆生物：细胞因子胆红素吸附树脂项目入选工信部揭榜挂帅
健帆生物：公司一次性使用血浆分离器产品采用德国进口聚醚砜膜
证券之星 · 04-30
健帆生物：公司一次性使用血浆分离器产品采用德国进口聚醚砜膜
健帆生物：公司金鼎二期项目于2026年1月奠基动工，目前尚在建设期，预计明年建成
证券之星 · 04-30
健帆生物：公司金鼎二期项目于2026年1月奠基动工，目前尚在建设期，预计明年建成
健帆生物（300529）2026年一季报简析：营收净利润同比双双增长
证券之星 · 04-29
健帆生物（300529）2026年一季报简析：营收净利润同比双双增长
股市必读：健帆生物年报 - 第四季度单季净利润同比增长178.67%
证券之星 · 04-29
股市必读：健帆生物年报 - 第四季度单季净利润同比增长178.67%
国金证券：给予健帆生物买入评级
证券之星 · 04-28
国金证券：给予健帆生物买入评级
图解健帆生物年报：第四季度单季净利润同比增长178.67%
证券之星 · 04-28
图解健帆生物年报：第四季度单季净利润同比增长178.67%
健帆生物（300529）披露2026年第一季度健帆转债转股情况，4月3日股价下跌2.75%
证券之星 · 04-03
健帆生物（300529）披露2026年第一季度健帆转债转股情况，4月3日股价下跌2.75%
股市必读：健帆生物（300529）3月25日董秘有最新回复
证券之星 · 03-26
股市必读：健帆生物（300529）3月25日董秘有最新回复
健帆生物：健福制药为公司持股10%的参股子公司
证券之星 · 03-25
健帆生物：健福制药为公司持股10%的参股子公司
健帆生物：公司深圳中心已于2026年1月揭牌启用
证券之星 · 03-25
健帆生物：公司深圳中心已于2026年1月揭牌启用
健帆生物：公司所处行业为“专用设备制造业”
证券之星 · 03-17
健帆生物：公司所处行业为“专用设备制造业”
暂无数据
公司概况
公司名称：
健帆生物科技集团股份有限公司
所属行业：
专用设备制造业
上市日期：
2016-08-02
主营业务：
健帆生物科技集团股份有限公司的主营业务是生物材料和高科技医疗器械的研发、生产及销售。公司的主要产品是一次性使用血液灌流器、一次性使用血浆胆红素吸附器、管路产品、血液净化设备、血浆分离器、血液透析粉液产品。
发行价格：
10.80
{"stockData":{"symbol":"300529","market":"SZ","secType":"STK","nameCN":"健帆生物","latestPrice":16.74,"timestamp":1780901613000,"preClose":17.22,"halted":0,"volume":5423000,"delay":0,"changeRate":-0.0279,"floatShares":512000000,"shares":799000000,"eps":0.707,"marketStatus":"交易中","change":-0.48,"latestTime":"06-08 14:53:33","open":16.89,"high":17.28,"low":16.51,"amount":91061800,"amplitude":0.0447,"askPrice":16.75,"askSize":23,"bidPrice":16.73,"bidSize":42,"shortable":0,"etf":0,"ttmEps":0.707,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780902000000},"marketStatusCode":2,"adr":0,"adjPreClose":17.22,"symbolType":"stock","openAndCloseTimeList":[[1780882200000,1780889400000],[1780894800000,1780902000000]],"highLimit":18.94,"lowLimit":15.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":798605275,"isCdr":false,"pbRate":3.84,"roa":"--","peRate":23.677511,"roe":"6.15%","epsLYR":0.69,"committee":-0.167364,"marketValue":13369000000,"turnoverRate":0.0106,"status":1,"floatMarketCap":8579000000},"requestUrl":"/m/hq/s/300529/tweets","defaultTab":"tweets","newsList":[{"id":"2640958381","title":"健帆生物（300529）披露健帆转债恢复转股的提示性公告，6月1日股价上涨3.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640958381","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640958381?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:52","pubTimestamp":1780307524,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，健帆生物报收于18.26元，较前一交易日上涨3.22%，最新总市值为145.83亿元。该股当日开盘17.71元，最高18.28元，最低17.63元，成交额达1.15亿元，换手率为1.24%。近日，健帆生物科技集团股份有限公司发布《关于健帆转债恢复转股的提示性公告》。根据规定，该可转债将于2026年6月1日，即股权登记日后的第一个交易日起恢复转股。转股起止日期为2021年12月29日至2027年6月22日。公司提醒健帆转债持有人注意相关安排。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100027957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638555012","title":"健帆生物（300529）披露2025年度权益分派实施公告，5月25日股价下跌1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638555012","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638555012?lang=zh_cn&edition=full","pubTime":"2026-05-25 22:39","pubTimestamp":1779719957,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，健帆生物报收于18.57元，较前一交易日下跌1.17%，最新总市值为148.3亿元。该股当日开盘18.78元，最高18.9元，最低18.38元，成交额达8697.95万元，换手率为0.91%。健帆生物于近日发布2025年度权益分派实施公告，以扣除回购股份后的总股本为基数，向全体股东每10股派发现金红利5.20元（含税），不送红股，不以资本公积金转增股本。因回购股份不参与分红，除权除息价格按总股本折算为每股扣除0.5042147元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500034195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637188563","title":"健帆生物（300529）披露健帆转债暂停转股公告，5月22日股价上涨0.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637188563","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637188563?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:40","pubTimestamp":1779442858,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，健帆生物报收于18.79元，较前一交易日上涨0.54%，最新总市值为150.06亿元。近日，健帆生物科技集团股份有限公司发布《关于实施权益分派期间健帆转债暂停转股的公告》。公告显示，因实施2025年度权益分派，公司可转换公司债券“健帆转债”自2026年5月25日起暂停转股，暂停期间债券正常交易；恢复转股时间为2025年度权益分派股权登记日后的第一个交易日；转股期为2021年12月29日至2027年6月22日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200033767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636843854","title":"健帆生物（300529）披露2025年度股东会决议公告，5月20日股价下跌1.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636843854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636843854?lang=zh_cn&edition=full","pubTime":"2026-05-20 17:52","pubTimestamp":1779270734,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，健帆生物报收于18.88元，较前一交易日下跌1.41%，最新总市值为150.78亿元。该股当日开盘19.1元，最高19.1元，最低18.75元，成交额达7549.72万元，换手率为0.78%。健帆生物于近日披露《2025年度股东会决议公告》。会议还选举产生了第六届董事会非独立董事和独立董事。所有提案均获通过，表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000034462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634404964","title":"健帆生物最新公告：新产品一次性使用连续性血液净化管路取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2634404964","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634404964?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:22","pubTimestamp":1778491366,"startTime":"0","endTime":"0","summary":"健帆生物(300529.SZ)公告称，公司于近日收到国家药品监督管理局颁发的《医疗器械注册证》，新产品一次性使用连续性血液净化管路已取得第三类医疗器械注册证。该产品用于血液净化治疗时承担体外血液和液体通路的功能，可配合连续性血液净化设备使用，适配多种临床治疗模式，进一步完善公司血液净化产品线布局，提升整体竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100023856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1100","BK1574","159883","BK1583","BK0251","300529","09996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633920024","title":"股市必读：健帆生物（300529）4月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2633920024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633920024?lang=zh_cn&edition=full","pubTime":"2026-05-06 06:00","pubTimestamp":1778018447,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，健帆生物报收于19.04元，下跌0.1%，换手率1.09%，成交量5.59万手，成交额1.07亿元。董秘最新回复投资者： 十分欣喜公司一季报业绩还可以，感谢全体健帆人为股东做出的努力！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632670135","title":"每周股票复盘：健帆生物（300529）Q1净利增16.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632670135","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632670135?lang=zh_cn&edition=full","pubTime":"2026-05-03 07:02","pubTimestamp":1777762938,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，健帆生物报收于19.04元，较上周的18.58元上涨2.48%。本周，健帆生物4月28日盘中最高价报19.87元。本周关注点来自业绩披露要点：健帆生物2026年一季报显示，归母净利润2.21亿元，同比上升16.81%。股本股东变化股东户数变动截至2026年3月31日，健帆生物股东户数为4.79万户，较2025年12月31日减少1637.0户，减幅3.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300001691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631897326","title":"健帆生物：HAHD罗马共识已正式发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2631897326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631897326?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:06","pubTimestamp":1777539972,"startTime":"0","endTime":"0","summary":"该共识已正式发布。2026年3月，一项关于新型体外血液净化技术——血液吸附联合血液透析的重磅共识在国际肾脏病领域顶级期刊《Nephrology Dialysis Transplantation》正式发布。共识明确血液吸附联合血液透析为“互补”策略，强调以患者为中心的多维评估与个体化、阶梯式治疗方案，并证实其良好安全性与兼容性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631689162","title":"健帆生物：细胞因子胆红素吸附树脂项目入选工信部揭榜挂帅","url":"https://stock-news.laohu8.com/highlight/detail?id=2631689162","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631689162?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:03","pubTimestamp":1777539792,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物04月30日在投资者关系平台上答复投资者关心的问题。截至目前该项目尚未量产。2025年8月，公司“细胞因子胆红素吸附树脂”项目入选工信部第二批生物医用材料创新任务“揭榜挂帅”入围名单，是广东省唯一入围细胞因子胆红素吸附树脂高分子材料研制项目的单位。如有重大进展公司将及时公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631689131","title":"健帆生物：公司一次性使用血浆分离器产品采用德国进口聚醚砜膜","url":"https://stock-news.laohu8.com/highlight/detail?id=2631689131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631689131?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:03","pubTimestamp":1777539787,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物(300529)04月30日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，健帆生物通过欧洲MDR认证的血液分离器所用的聚醚砜材料是否企业自己生产？这类材料还有什么具体应用？健帆生物回复：您好。公司一次性使用血浆分离器产品采用德国进口聚醚砜膜。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["FDXSmain","BK0251","300529","FDXMmain","FDAXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631686080","title":"健帆生物：公司金鼎二期项目于2026年1月奠基动工，目前尚在建设期，预计明年建成","url":"https://stock-news.laohu8.com/highlight/detail?id=2631686080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631686080?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:51","pubTimestamp":1777539074,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物04月30日在投资者关系平台上答复投资者关心的问题。公司表示扩产是为了发挥规模优势，但财务上存在滞后效应。公司金鼎二期项目于2026年1月奠基动工，目前尚在建设期，预计明年建成。未来转固后将严格按照相关会计准则处理，并在定期报告中披露具体数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000054254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631955594","title":"健帆生物（300529）2026年一季报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2631955594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631955594?lang=zh_cn&edition=full","pubTime":"2026-04-29 08:58","pubTimestamp":1777424322,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期健帆生物发布2026年一季报。根据财报显示，健帆生物营收净利润同比双双增长。截至本报告期末，公司营业总收入5.61亿元，同比上升2.33%，归母净利润2.21亿元，同比上升16.81%。本次财报公布的各项数据指标表现尚佳。去年的净利率为26.43%，算上全部成本后，公司产品或服务的附加值高。生意拆解：公司过去三年净经营资产收益率分别为20.2%/36%/23.2%，净经营利润分别为4.26亿/8.14亿/5.32亿元，净经营资产分别为21.03亿/22.61亿/22.95亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900027964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631500537","title":"股市必读：健帆生物年报 - 第四季度单季净利润同比增长178.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631500537","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631500537?lang=zh_cn&edition=full","pubTime":"2026-04-29 06:56","pubTimestamp":1777416998,"startTime":"0","endTime":"0","summary":"来自股本股东变化：截至2026年3月31日股东户数环比下降3.3%，户均持股上升至1.67万股，筹码集中度提升。股本股东变化股东户数变动截至2026年3月31日公司股东户数为4.79万户，较2025年12月31日减少1637.0户，减幅为3.3%；户均持股数量由上期的1.61万股增至1.67万股，户均持股市值为29.53万元。其中2025年第四季度单季度主营收入4.56亿元，同比下降5.36%；单季度归母净利润7959.12万元，同比上升178.67%；单季度扣非净利润7484.12万元，同比上升195.34%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900017213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630503344","title":"国金证券：给予健帆生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2630503344","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630503344?lang=zh_cn&edition=full","pubTime":"2026-04-28 08:45","pubTimestamp":1777337124,"startTime":"0","endTime":"0","summary":"国金证券股份有限公司甘坛焕,何冠洲近期对健帆生物进行研究并发布了研究报告《以价换量拓新局，创新出海促增长》，给予健帆生物买入评级。受行业需求减少及市场竞争加剧等因素影响，公司整体收入同比下降。2025年KHA130实现收入1.22亿元，同比+10.90%；占公司整体销售比重为6.05%；实现销量41.58万支，同比+88.03%。最新盈利预测明细如下：该股最近90天内共有1家机构给出评级，买入评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800027636.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630311689","title":"图解健帆生物年报：第四季度单季净利润同比增长178.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630311689","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630311689?lang=zh_cn&edition=full","pubTime":"2026-04-28 02:04","pubTimestamp":1777313061,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物2025年年报显示，当年度公司主营收入20.12亿元，同比下降24.86%；归母净利润5.33亿元，同比下降35.04%；扣非净利润5.13亿元，同比下降34.16%；其中2025年第四季度，公司单季度主营收入4.56亿元，同比下降5.36%；单季度归母净利润7959.12万元，同比上升178.67%；单季度扣非净利润7484.12万元，同比上升195.34%；负债率35.82%，投资收益5347.59万元，财务费用4164.41万元，毛利率78.7%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800005647.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624663823","title":"健帆生物（300529）披露2026年第一季度健帆转债转股情况，4月3日股价下跌2.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624663823","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624663823?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:22","pubTimestamp":1775226139,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，健帆生物报收于17.31元，较前一交易日下跌2.75%，最新总市值为138.24亿元。该股当日开盘17.8元，最高17.83元，最低17.27元，成交额达5620.81万元，换手率为0.63%。健帆生物近日披露《关于2026年第一季度健帆转债转股情况的公告》。公告显示，2026年第一季度，共有10张健帆转债完成转股，合计转为25股公司股票。截至2026年3月31日，剩余可转债为9,998,302张，票面金额999,830,200元。公告还列示了可转债发行、转股期限、历次转股价格调整及回售情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622708005","title":"股市必读：健帆生物（300529）3月25日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2622708005","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622708005?lang=zh_cn&edition=full","pubTime":"2026-03-26 01:42","pubTimestamp":1774460540,"startTime":"0","endTime":"0","summary":"截至2026年3月25日收盘，健帆生物报收于17.72元，下跌0.11%，换手率0.6%，成交量3.1万手，成交额5504.98万元。董秘最新回复投资者： 请问贵公司深圳中心启用了没有？健福制药为公司持股10%的参股子公司。目前暂无相关收购计划。健帆医疗器械产业项目二期已于2026年1月奠基动工，预计2027年下半年建成。交易信息汇总资金流向3月25日主力资金净流出814.72万元；游资资金净流入298.03万元；散户资金净流入516.69万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032600002120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622021631","title":"健帆生物：健福制药为公司持股10%的参股子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2622021631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622021631?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:27","pubTimestamp":1774430829,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物03月25日在投资者关系平台上答复投资者关心的问题。有没有收购成为全资子公司的想法？健福制药为公司持股10%的参股子公司。目前暂无相关收购计划。健帆医疗器械产业项目二期已于2026年1月奠基动工，预计2027年下半年建成。公司对外投资及项目建设进展等情况，公司将根据规定及时履行信息披露义务，敬请关注公司公告动态。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500033140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK1191","BK1574","BK0251","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622021637","title":"健帆生物：公司深圳中心已于2026年1月揭牌启用","url":"https://stock-news.laohu8.com/highlight/detail?id=2622021637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622021637?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:27","pubTimestamp":1774430828,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物(300529)03月25日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司深圳中心启用了没有？对对外贸易有什么影响？健帆生物回复：您好！公司深圳中心已于2026年1月揭牌启用，是公司“海外业务的桥头堡”与“高端医疗设备研发的新基地”，未来将助力公司海外业务拓展，强化公司研发创新能力。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500033136.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300529"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620444056","title":"健帆生物：公司所处行业为“专用设备制造业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2620444056","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620444056?lang=zh_cn&edition=full","pubTime":"2026-03-17 17:18","pubTimestamp":1773739089,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物(300529)03月17日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司算消费行业吗健帆生物回复：您好。根据《上市公司行业分类指引》，公司所处行业为“专用设备制造业”，行业代码为C35，公司主要产品为三类医疗器械，属于医疗器械行业中血液净化行业。公司主营业务为血液净化相关产品（血液灌流器、血液净化设备、透析粉液等）的研发、生产和销售；公司产品主要用于治疗肾病、肝病、危急重症、风湿免疫等领域的患者。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700029768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300529","BK0251"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780901617836,"stockEarnings":[{"period":"1week","weight":-0.0263},{"period":"1month","weight":-0.0838},{"period":"3month","weight":-0.0669},{"period":"6month","weight":-0.1211},{"period":"1year","weight":-0.1865},{"period":"ytd","weight":-0.0996}],"compareEarnings":[{"period":"1week","weight":-0.01},{"period":"1month","weight":-0.0318},{"period":"3month","weight":-0.0234},{"period":"6month","weight":0.032},{"period":"1year","weight":0.1902},{"period":"ytd","weight":0.0148}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"健帆生物科技集团股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"47950人(较上一季度减少3.30%)","perCapita":"10687股","listingDate":"2016-08-02","address":"广东省珠海市香洲区高新区科技六路98号","registeredCapital":"79860万元","survey":" 健帆生物科技集团股份有限公司的主营业务是生物材料和高科技医疗器械的研发、生产及销售。公司的主要产品是一次性使用血液灌流器、一次性使用血浆胆红素吸附器、管路产品、血液净化设备、血浆分离器、血液透析粉液产品。","listedPrice":10.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健帆生物(300529)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健帆生物,300529,健帆生物股票,健帆生物股票老虎,健帆生物股票老虎国际,健帆生物行情,健帆生物股票行情,健帆生物股价,健帆生物股市,健帆生物股票价格,健帆生物股票交易,健帆生物股票购买,健帆生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健帆生物(300529)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健帆生物(300529)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}